46 results
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
26 May 22
Current report (foreign)
5:11pm
Society of Clinical Oncology Annual Meeting
Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid … in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
6-K
MREO
Mereo Biopharma Group Plc
26 May 22
Current report (foreign)
5:11pm
titled “Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society
6-K
EX-99.3
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
and a poster session, respectively, at the American Thoracic Society (ATS) 2023 annual meeting in May 2023.
Data from the ongoing placebo-controlled … at the upcoming European Society for Medical Oncology (ESMO) Annual Meeting, being held October 20-24, 2023 in Madrid, Spain.
Etigilimab, in combination
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
1 Oct 21
Current report (foreign)
4:43pm
) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
Previously reported data demonstrated dose-dependent, statistically … Imperfecta (OI). Data were presented at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting in an oral presentation
6-K
MREO
Mereo Biopharma Group Plc
1 Oct 21
Current report (foreign)
4:43pm
) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting.”
SIGNATURES
Pursuant to the requirements of the Securities Exchange
F-4/A
EX-10.7.1
uo3 2yd05gfe
15 Mar 19
Registration of securities (foreign) (amended)
5:08pm
6-K
EX-99.1
4yp4z3auy
2 Jun 21
Current report (foreign)
8:24am
6-K
EX-99.1
3v9alyup yt0cu
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
06q8kz4
2 Jun 22
Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
9:07am
6-K
EX-99.1
wm4c8
17 Sep 19
Current report (foreign)
8:06am
6-K
EX-99.1
x2qksni9k cp79zo07yq
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.1
uovi0w
22 Nov 19
Current report (foreign)
9:29am
20-F
EX-4.19
0otppv4383s0c osllx
29 Apr 19
Annual report (foreign)
4:59pm
F-4
EX-10.7
q7ao4h
25 Jan 19
Registration of securities (foreign)
12:00am
6-K
EX-99.1
pufu04njosm28iz872ls
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
wdk1 759y5bmj
29 Apr 19
Current report (foreign)
12:09pm
6-K
EX-99.2
fx83xe0j9vra k0j0
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
S-8
EX-99.1
ozmrni8gz 9r4q9
21 May 19
Registration of securities for employees
1:53pm
S-8
EX-99.1
msqteiuu
15 Jan 21
Registration of securities for employees
4:21pm